TDOC

Over the past six months, Teladoc Health's stock (TDOC) has declined, decreasing by 31.58% over the last 12 months and 8.90% in the past month as of October 7, 2026. Key events impacting the stock include Q2 2026 financial results reported on July 29, 2026, which showed a 4% year-over-year revenue decline, missed market expectations, and led to a cut in the full-year outlook, causing a 28.32% stock drop. Executive changes included Michael Grasher's appointment as CFO in August 2026 and a Chief Legal Officer transition in September 2026. Product launches and partnerships included a collaboration with Walmart in May 2026, the launch of Teladoc One in July 2026, and the introduction of AI capabilities SoloVitals and SoloScribe in October 2026. Insider selling involved 14 sales and no purchases, with a chief accounting officer selling shares to cover taxes. Macroeconomic factors such as elevated Treasury yields and rising interest rates also negatively impacted the growth stock.